One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The crucial role of clinicopathological correlation in COVID-19-related cutaneous manifestations
F. Rongioletti
doi : 10.1111/jdv.17414
Volume 35, Issue 9 p. 1742-1743
Skin is one of target organs affected by the novel coronavirus SARS-CoV-2, and a fast body of literature has emerged on cutaneous manifestations related to coronavirus disease 2019 (COVID-19). However, in contrast with the abundance of epidemiological and clinical reports, histopathologic characterization of skin manifestations is more limited, based on small case series and individual observations. A plausible explanation is that in view of the greater severity of lung and multiorgan involvement, invasive skin assessment has been postponed avoiding additional sufferance to the patient. Moreover, at least initially, there were many difficulties in obtaining skin biopsies in COVID-19 patients, and the transient course of many types of eruption has complicated the issue. Nevertheless, skin histopathology might be crucial to differentiate clinically similar lesions and deepen the comprehension of pathogenetic mechanisms that are effectively associated with COVID-19. In this issue, Barrera-Godínez et al describe a series of 28 inpatients with a confirmed diagnosis of COVID-19 who during their admission developed skin lesions, which have been studied with biopsies and the accompanying histopathological findings.1 The most common clinical patterns of presentations included morbilliform- and urticaria-like exanthems in 17 patients (77%). Spongiosis, basal vacuolar degeneration, a superficial perivascular mixed infiltrate composed of lymphocytes, histiocytes with neutrophils and eosinophils were the histopathological hallmarks of these lesions. Although these findings were consistent with previous reports,2, 3 they do not show any specific signs that could help to differentiate COVID-19 skin lesions from non-COVID-19 causes such as drugs or other viral infections. However, some aspects of interface vacuolar dermatitis that have been observed in all of the urticaria-like exanthems are of interest because they would not be normally expected in acute common urticaria. Therefore, it has been suggested that a skin biopsy is useful in differentiating urticaria-like viral exanthems from acute urticaria in the setting of COVID-19. Additional histopathologic findings described in the literature in COVID-19-related exanthematous eruptions, such as dyskeratotic keratinocytes, herpes-like changes, Grover-like changes, nest of Langerhans cells, subepidermal oedema, periadnexal lymphocytic infiltrate and thrombosed vessels have not been found in the current patients.4 Whether this is due to an evaluation of lesions of different pathogenesis or to an early administration of corticosteroids and heparin is yet to be verified. A peculiar pattern of a purely papular eruption made by disseminated, discrete, red non-confluent papules distinct from previous reports of COVID-19-associated exanthems that featured a maculopapular morphology was observed in four patients; in this setting, histopathology showed a non-specific variable, inflammatory perivascular pattern with again the presence of interface vacuolar alteration. Histological features of neutrophilic eccrine hidradenitis were also observed in one of these patients. Further studies are needed to confirm whether this purely papular presentation could be actually linked to COVID-19. It is likely that these morbilliform eruptions are not related to a direct viral cytopathic effect but they rather correspond to a paraviral phenomenon, also considering that the presence of SARS-CoV2 was not found when searched in cutaneous samples by in situ hybridization and immunohistochemistry5 In any case, when evaluating a maculopapular rash of unknown origin, and in the appropriate epidemiological context, COVID-19 should be considered in the differential diagnosis, especially if the histopathological findings show a vacuolar pattern of interface dermatitis.
Clinical and trichoscopic aspects of scalp psoriasis: commentary to ‘Clinical and trichoscopic features in various forms of scalp psoriasis’ by F. Bruni et al.
F. Lacarrubba
doi : 10.1111/jdv.17527
Volume 35, Issue 9 p. 1744-1745
Scalp involvement is very common in psoriasis, being present in up to 80% of patients. The clinical presentation is variable, ranging from minimal scaling to thick plaques covering the whole scalp. Prompt diagnosis and treatment are important, as scalp psoriasis may greatly impact on patients' quality of life (QoL) due to itching, pain, bleeding and feelings of embarrassment due to scales clearly visibly on dark clothing, all causing severe psychological and social impairment, especially in young subjects.1, 2 The special consideration for scalp psoriasis, that is traditionally considered a difficult-to-treat disease, is also highlighted by the increasing number of studies evaluating the use of biologics and small molecules for its management.3
How does atopic dermatitis in childhood and adolescence affect educational success?
M. Möhrenschlager,P. Demolli,V. Schmidt,
doi : 10.1111/jdv.17518
Volume 35, Issue 9 p. 1746-1746
Different aspects may impair completion of education in atopic dermatitis (AD) patients, including the burdens of direct costs (e.g. medication), indirect costs (e.g. absenteeism, presenteeism) and opportunity costs (e.g. affection on sleep pattern).1, 2 By starting from childhood and persisting later on, these aspects can have a substantial impact on education and career of patients.
Pioneers in Dermatology and Venereology: An Interview with Professor Ervin Epstein, Jr
E. Epstein Jr
doi : 10.1111/jdv.17505
Volume 35, Issue 9 p. 1747-1749
European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I
H. Rashid,A. Lamberts,L. Borradori,S. Alberti-Violetti,R.J. Barry,M. Caproni,B. Carey,M. Carrozzo,F. Caux,G. Cianchini,A. Corrà,G.F.H. Diercks,F.G. Dikkers,G. Di Zenzo,C. Feliciani,G. Geerling,G. Genovese,M. Hertl,P. Joly,A.V. Marzano,J.M. Meijer,V. Mercadante,D.F. Murrell,M. Ormond,H.H. Pas,A. Patsatsi,C. Prost,S. Rauz,B.D. van Rhijn,M. Roth,E. Schmidt,J. Setterfield,G. Zambruno,D. Zillikens,B. Horváth
doi : 10.1111/jdv.17397
Volume 35, Issue 9 p. 1750-1764
This guideline on mucous membrane pemphigoid (MMP) has been elaborated by the Task Force for Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology (EADV) with a contribution of physicians from all relevant disciplines and patient organizations. It is a S3 consensus-based guideline encompassing a systematic review of the literature until June 2019 in the MEDLINE and EMBASE databases. This first part covers methodology, the clinical definition of MMP, epidemiology, MMP subtypes, immunopathological characteristics, disease assessment and outcome scores. MMP describes a group of autoimmune skin and mucous membrane blistering diseases, characterized by a chronic course and by predominant involvement of the mucous membranes, such as the oral, ocular, nasal, nasopharyngeal, anogenital, laryngeal and oesophageal mucosa. MMP patients may present with mono- or multisite involvement. Patients’ autoantibodies have been shown to be predominantly directed against BP180 (also called BPAG2, type XVII collagen), BP230, laminin 332 and type VII collagen, components of junctional adhesion complexes promoting epithelial stromal attachment in stratified epithelia. Various disease assessment scores are available, including the Mucous Membrane Pemphigoid Disease Area Index (MMPDAI), the Autoimmune Bullous Skin disorder Intensity Score (ABSIS), the ‘Cicatrising Conjunctivitis Assessment Tool’ and the Oral Disease Severity Score (ODSS). Patient-reported outcome measurements (PROMs), including DLQI, ABQOL and TABQOL, can be used for assessment of quality of life to evaluate the effectiveness of therapeutic interventions and monitor disease course.
Scabies itch: an update on neuroimmune interactions and novel targets
H.S. Kim,T. Hashimoto,K. Fischer,C. Bernigaud,O. Chosidow,G. Yosipovitch,
doi : 10.1111/jdv.17334
Volume 35, Issue 9 p. 1765-1776
Frequently described as ‘the worst itch’ one can ever experience scabies itch is the hallmark of Sarcoptes scabiei mite infestation. Notably, the itchiness often persists for weeks despite scabicides therapy. The mechanism of scabies itch is not yet fully understood, and effective treatment modalities are still missing which can severely affect the quality of life. The aim of this review is to provide an overview of the scope of itch in scabies and highlight candidate mechanisms underlying this itch. We herein discuss scabies itch, with a focus on the nature, candidate underlying mechanisms and treatment options. We also synthesize this information with current understanding of the mechanisms contributing to non-histaminergic itch in other conditions. Itch is a major problem in scabies and can lead to grave consequences. We provide the latest insights on host–mite interaction, secondary microbial infection and neural sensitization with special emphasis on keratinocytes and mast cells to better understand the mechanism of itch in scabies. Also, the most relevant current modalities remaining under investigation that possess promising perspectives for scabies itch (i.e. protease-activated receptor-2 (PAR-2) inhibitor, Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist) are discussed. Greater understanding of these diverse mechanisms may provide a rational basis for the development of improved and targeted approaches to control itch in individuals with scabies.
Efficacy and prognostic factors of adjuvant radiotherapy for cutaneous squamous cell carcinoma: A systematic review and meta-analysis
J. Zhang,Y. Wang,W.A. Wijaya,Z. Liang,J. Chen,
doi : 10.1111/jdv.17330
Volume 35, Issue 9 p. 1777-1787
Although adjuvant radiotherapy has been used for cutaneous squamous cell carcinoma, its outcome benefits, especially for patients with clear surgical margins, have not been statistically estimated, and the characteristics that can indicate patients who require adjuvant therapy need to be validated with more evidence. We conducted a systematic review and meta-analysis of literature on the survival outcomes and prognostic factors in patients with cSCC treated by surgery with or without adjuvant radiotherapy. Twenty related studies involving 2605 patients met our inclusion criteria. The significant survival outcomes of adjuvant radiotherapy included lower recurrence (OR, 0.56; 95% CI, 0.36–0.85), longer disease-free survival (OR, 2.17; 95% CI, 1.23–3.83) and longer overall survival (OR, 2.94; 95% CI, 1.75–4.91). Significant prognostic factors for poor outcomes were perineural invasion (HR, 1.61; 95% CI, 1.24–2.09), involved surgical margins (HR, 2.34; 95% CI, 1.42–3.83) and immunosuppression (HR, 3.02; 95% CI, 2.14–4.25) while adjuvant radiotherapy significantly contributed to better overall survival (HR, 0.47; 95% CI, 0.34–0.65). In conclusion, this systematic review suggests that in cutaneous squamous cell carcinoma patients with risk factors, including metastasis to the parotid gland, perineural invasion and immunosuppression, the use of adjuvant radiotherapy may be beneficial irrespective of surgical margin status.
Isolated autosomal recessive woolly hair/hypotrichosis: genetics, pathogenesis and therapies
M. Akiyama
doi : 10.1111/jdv.17350
Volume 35, Issue 9 p. 1788-1796
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis
J.I. Silverberg,J.P. Thyssen,K. Fahrbach,K. Mickle,J.C. Cappelleri,W. Romero,M.C. Cameron,D.E. Myers,C. Clibborn,M. DiBonaventura,
doi : 10.1111/jdv.17351
Volume 35, Issue 9 p. 1797-1810
Given the lack of head-to-head studies of systemic therapies in moderate-to-severe atopic dermatitis (AD), network meta-analyses (NMAs) can provide comparative efficacy and safety data to inform clinical decision-making. In this NMA, eligible randomized controlled trials (RCTs) published before 24 October 2019 were identified by a systematic literature review. Short-term (12–16 weeks) efficacy (Investigator’s Global Assessment [IGA] and Eczema Area and Severity Index [EASI] responses), patient-reported outcomes (PROs) and safety data from each trial were abstracted and analysed separately for monotherapy and combination therapy (systemic plus topical anti-inflammatory therapy). RCTs were analysed in fixed-effects and random-effects Bayesian NMA models. Overall, 19 phase 2 and phase 3 RCTs of abrocitinib, baricitinib, dupilumab, lebrikizumab, nemolizumab, tralokinumab and upadacitinib were included. In monotherapy RCTs, upadacitinib 30 mg once daily (QD) had the numerically highest efficacy (83.6% achieved ?50% improvement in EASI [EASI-50 response]), followed by abrocitinib 200 mg QD (74.6%), upadacitinib 15 mg QD (70.5%), dupilumab 300 mg every 2 weeks (Q2W) (63.4%) and abrocitinib 100 mg QD (56.7%). Similar trends in EASI-75 and EASI-90 response were observed. In combination therapy RCTs, abrocitinib 200 mg QD had the highest EASI-50 (86.6%), followed by dupilumab 300 mg Q2W (82.4%) and abrocitinib 100 mg QD (79.7%). Similar findings were observed for IGA response and PROs. In monotherapy and combination therapy RCTs, the probability of treatment-emergent adverse events (TEAEs) was higher among all active treatments than with placebo (except for dupilumab 300 mg Q2W [odds ratio (OR), 0.96; 95% credible interval (CrI), 0.45–2.18] and abrocitinib 100 mg QD [OR, 0.95; 95% CrI, 0.35–2.66] in combination therapy RCTs), although active treatments did not significantly differ from one another. Abrocitinib, dupilumab and upadacitinib were consistently the most effective systemic therapies in adult and adolescent patients with AD, with no significant TEAE differences in short-term RCTs.
Lentigo maligna: defining margins and predictors of recurrence utilizing clinical, dermoscopic, confocal microscopy and histopathology features
P. Star,R.V. Rawson,M. Drummond,S. Lo,R.A. Scolyer,P. Guitera,
doi : 10.1111/jdv.17349
Volume 35, Issue 9 p. 1811-1820
Lentigo maligna (LM) is a subtype of melanoma in situ with poorly defined margins and a high recurrence rate. The biological behaviour of LM appears to differ widely between cases, from biologically indolent to biologically active variants, with some patients experiencing multiple recurrences. It is not known whether this is secondary to inadequate margins, field cancerization or the innate biology of the lesion itself.
Screening for second malignancies in mycosis fungoides: non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma
A. Goyal,D. O’Leary,K. Goyal,N. Rubin,M. Janakiram,
doi : 10.1111/jdv.17384
Volume 35, Issue 9 p. 1821-1829
Patients with mycosis fungoides (MF) are at increased risk of developing non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), lung cancer, bladder cancer and melanoma. The characteristics of patients developing these malignancies have not been specifically delineated. In addition, there are no established guidelines for screening MF patients for second malignancies.
Clinical and trichoscopic features in various forms of scalp psoriasis
F. Bruni,A. Alessandrini,M. Starace,G. Orlando,B.M. Piraccini,
doi : 10.1111/jdv.17354
Volume 35, Issue 9 p. 1830-1837
Scalp psoriasis is often undiagnosed or inadequately treated. The patient himself underestimates the seriousness of this hair disease and consults too late to a dermatologist.
Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study
D. Ioannides,N. Antonakopoulos,S. Georgiou,V. Chasapi,I. Katsantonis,A. Drosos,D. Rigopoulos,C. Antoniou,G. Anastasiadis,I. Bassukas,D. Ioannidou,A. Protopapa,O. Neofotistou,K. Krasagakis,P. Aronis,M. Papageorgiou,E. Lazaridou,A. Patsatsi,I. Lefaki,A.V. Roussaki-Schulze,F. Satra,Z. Anagnostopoulos,M. Papakonstantis
doi : 10.1111/jdv.17392
Volume 35, Issue 9 p. 1838-1848
Apremilast is an oral phosphodiesterase-4 inhibitor indicated for patients with moderate-to-severe chronic plaque psoriasis and active psoriatic arthritis.
Childhood atopic dermatitis is associated with a decreased chance of completing education later in life: a register-based cohort study
K. Pálsson,R.M. Slagor,E.M. Flachs,L.B. Nørreslet,T. Agner,N.E. Ebbehøj,
doi : 10.1111/jdv.17346
Volume 35, Issue 9 p. 1849-1858
Atopic dermatitis (AD) has far-reaching consequences in childhood and later in working life, but information on how it affects completion of education is sparse.
The effect of anxiety, psychopathological symptoms and personality traits on response to treatment in male patients with anogenital warts: a prospective study
G. Tyros,C. Papageorgiou,A. Kanelleas,O. Kotsafti,E. Spyridonos,S. Gregoriou,A. Tagka,A. Stratigos,E. Nicolaidou,
doi : 10.1111/jdv.17324
Volume 35, Issue 9 p. 1859-1864
In the era of precision medicine, identification of possible predictive factors of clinical response to treatment is fundamental. This need is particularly strong for anogenital warts (AGW), because there are several treatment modalities with different clearance and recurrence rates. However, data regarding the effect of mental health parameters on response to treatment in patients with AGW are lacking.
Not all that glitters is COVID-19: a case series demonstrating the need for histopathology when skin findings accompany SARS-CoV-2 infection
A. Barrera-Godínez,S. Méndez-Flores,M. Gatica-Torres,A. Rosales-Sotomayor,K.I. Campos-Jiménez,D.M. Carrillo-Córdova,M.C. Durand-Muñoz,G.L. Mena-Hernández,Y.K. Melchor-Mendoza,A.L. Ruelas-Villavicencio,A. García-Irigoyen,G.A. Acatitla-Acevedo,S. Toussaint-Caire,J. Domínguez-Cherit
doi : 10.1111/jdv.17381
Volume 35, Issue 9 p. 1865-1873
Descriptions of cutaneous findings associated with COVID-19 have not been consistently accompanied by histopathology or confirmatory testing for SARS-CoV-2.
Hereditary palmoplantar keratoderma – phenotypes and mutations in 64 patients
L. Harjama,V. Karvonen,K. Kettunen,O. Elomaa,E. Einarsdottir,H. Heikkilä,S. Kivirikko,P. Ellonen,J. Saarela,A. Ranki,J. Kere,K. Hannula-Jouppi,
doi : 10.1111/jdv.17314
Volume 35, Issue 9 p. 1874-1880
Hereditary palmoplantar keratodermas (PPK) represent a heterogeneous group of rare skin disorders with epidermal hyperkeratosis of the palms and soles, with occasional additional manifestations in other tissues. Mutations in at least 69 genes have been implicated in PPK, but further novel candidate genes and mutations are still to be found.
Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial
P.B. Lima,J.A.F. Dias,D.P. Cassiano,A.C.C. Esposito,L.D.B. Miot,E. Bagatin,H.A. Miot,
doi : 10.1111/jdv.17344
Volume 35, Issue 9 p. 1881-1887
Melasma can be refractory to treatment, and relapses are frequent. Thiamidol is a new potent tyrosinase inhibitor that has been found effective as a cosmeceutical for the depigmenting of melasma.
Development of a core outcome domain set for clinical research on capillary malformations (the COSCAM project)
G.B. Langbroek,A. Wolkerstorfer,S.E.R. Horbach,P.I. Spuls,K.M. Kelly,S.J. Robertson,M.I. van Raath,F. Al-Niaimi,T. Kono,P. Boixeda,H.J. Laubach,A.M. Badawi,A. Troilius Rubin,M. Haedersdal,W. Manuskiatti,C.M.A.M. van der Horst,D.T. Ubbink,the COSCAM study group
doi : 10.1111/jdv.17376
Volume 35, Issue 9 p. 1888-1895
Due to a large variety in treatment outcomes reported in therapeutic trials and lacking patient-relevant outcomes, it is hard to adequately compare and improve current therapies for patients with capillary malformations (CMs). The Core Outcome Set for Capillary Malformations (COSCAM) project aims to develop a core outcome set (COS) for use in future CM trials, in which we will first develop a core outcome (sub)domain set (CDS). Here, we describe the methods for the development of a CDS and present the results of the first development stage.
High variability in anatomic patterns of cutaneous photodamage: a population-based study
B. Betz-Stablein,S. Llewellyn,P. Bearzi,K. Grochulska,C. Rutjes,J.F. Aitken,M. Janda,P. O’Rouke,H.P. Soyer,A.C. Green,
doi : 10.1111/jdv.17352
Volume 35, Issue 9 p. 1896-1903
Skin cancer is strongly associated with photodamaged skin, but body sites are often referred to as ‘exposed’ or ‘unexposed’ to sun without recognizing extent of site-specific variation.
Non-acral skin manifestations during the COVID-19 epidemic: COVIDSKIN study by the French Society of Dermatology
R. Guelimi,R. Salle,L. Dousset,H. Assier,S. Fourati,Z. Bhujoo,S. Barbarot,C. Boulard,C. Cazanave,A. Colin,E. Kostrzewa,C. Lesort,A. Levy Roy,F. Lombart,J. Marco Bonnet,L. Marty,J.B. Monfort,L. Riffaud,M. Samimi,M. Tardieu,E. Sbidian,P. Wolkenstein,L. Le Cleach,M. Beylot-Barry
doi : 10.1111/jdv.17322
Volume 35, Issue 9 p. e539-e541
Adamantiades-Behçet's disease (Behçet's disease) and COVID-19
C.C. Zouboulis,J.A.M. van Laar,M. Schirmer,G. Emmi,F. Fortune,A. Gül,Y. Kirino,E.-S. Lee,P.P. Sfikakis,F. Shahram,G.R. Wallace,
doi : 10.1111/jdv.17325
Volume 35, Issue 9 p. e541-e543
Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID-19 vaccine: another piece of SARS-CoV-2 skin puzzle?
C. Mazzatenta,V. Piccolo,G. Pace,I. Romano,G. Argenziano,A. Bassi,
doi : 10.1111/jdv.17340
Volume 35, Issue 9 p. e543-e545
Recurrent injection-site reactions after incorrect subcutaneous administration of a COVID-19 vaccine
M. Gyldenløve,L. Skov,C.B. Hansen,P. Garred,
doi : 10.1111/jdv.17341
Volume 35, Issue 9 p. e545-e546
Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine
B.M. Cyrenne,F. Al-Mohammedi,J.G. DeKoven,R. Alhusayen,
doi : 10.1111/jdv.17342
Volume 35, Issue 9 p. e546-e548
Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy
E. Farinazzo,G. Ponis,E. Zelin,E. Errichetti,G. Stinco,C. Pinzani,A. Gambelli,N. De Manzini,L. Toffoli,A. Moret,M. Agozzino,C. Conforti,N. Di Meo,P. Schincariol,I. Zalaudek,
doi : 10.1111/jdv.17343
Volume 35, Issue 9 p. e548-e551
Heterogeneous red–white discoloration of the nail bed and distal onycholysis in a patient with COVID-19
B. Demir,E.I. Yuksel,D. Cicek,S. Turkoglu,
doi : 10.1111/jdv.17347
Volume 35, Issue 9 p. e551-e553
Androgenetic alopecia in women and men is not related to COVID-19 infection severity: a prospective cohort study of hospitalized COVID-19 patients
S. Torabi,M. Mozdourian,R. Rezazadeh,A. Payandeh,S. Badiee,E. Darchini-Maragheh,
doi : 10.1111/jdv.17353
Volume 35, Issue 9 p. e553-e556
Detection of a second outbreak of chilblain-like lesions during COVID-19 pandemic through teledermatology
L. Giraud-Kerleroux,M. Mongereau,C. Cassius,M. Mrad,C. Gary,C. Fiani,M. Ben Kahla,T. Mahevas,E. Zuelgaray,C. Skayem,C. Hua,K. Ezzedine,M. Bagot,J.-D. Bouaziz,T.A. Duong,
doi : 10.1111/jdv.17378
Volume 35, Issue 9 p. e556-e558
SARS-CoV-2: skin diseases, mask wearing and unpleasant sensations
B. Cribier,C. Taieb,M. Saint Aroman,J. Shourick,
doi : 10.1111/jdv.17380
Volume 35, Issue 9 p. e558-e560
SARS-CoV-2 mRNA vaccine-associated fixed drug eruption
D. Mintoff,D. Pisani,A. Betts,L. Scerri,
doi : 10.1111/jdv.17390
Volume 35, Issue 9 p. e560-e563
Urticarial vasculitis revealing immunolabelled nucleocapsid protein of SARS-CoV-2 in two Brazilian asymptomatic patients: the tip of the COVID-19 hidden iceberg?
P.R. Criado,R.F.J. Criado,R. Gianotti,B.A.Z. Abdalla,T.P.H. Pincelli,A.O. Michalany,N.S. Michalany,
doi : 10.1111/jdv.17391
Volume 35, Issue 9 p. e563-e566
Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain-like lesion during the COVID-19 pandemic
P. Moghadam,L. Frumholtz,L. Jaume,A. De Masson,M. Jachiet,E. Begon,L. Sulimovic,A. Petit,H. Bachelez,M. Bagot,J.-D. Bouaziz,C. Cassius,Saint-Louis CORE (COvid REsearch),
doi : 10.1111/jdv.17393
Volume 35, Issue 9 p. e566-e568
Dapsone-induced methaemoglobinaemia in leprosy: a close mimic of ‘happy hypoxia’ in the COVID-19 pandemic
T. Tripathi,A.R. Singh,R. Kapoor,A. Sinha,S. Ghosh,K. Kaur,D. Pokhariya,S. Maity,A. Tapadar,A. Chandra,
doi : 10.1111/jdv.17394
Volume 35, Issue 9 p. e568-e571
Autoantibodies in Covid-19 – a model for viral induced autoimmunity
J. Berger,S. Volc,
doi : 10.1111/jdv.17396
Volume 35, Issue 9 p. e571-e573
Increase in early syphilis diagnoses in the young heterosexual population of Reunion Island: surveillance data, 2010–2018
A. Etienne,S. Devos,E. Thore,N. Ndeikoudam Ngrango,R. Manaquin,Y. Koumar,L. Balloy,R. Rodet,L. Yemadje-Menudier,A. Bertolotti,
doi : 10.1111/jdv.17294
Volume 35, Issue 9 p. e573-e575
Associations between clinical variables and treatment regimens and hair density and calibre in female androgenetic alopecia patients: a retrospective study of 602 patients
H. Tuan,L. Yin,K. Lo Sicco,J. Shapiro,
doi : 10.1111/jdv.17281
Volume 35, Issue 9 p. e576-e578
The use of the internet by outpatients in dermatology: a multicentric, observational and cross-sectional study on frequency, motivations and feedback
M. Corazza,R. Forconi,A. Patrizi,L. Veneziano,A. Offidani,M. Paolinelli,L. Stingeni,K. Hansel,C. Foti,C. Barlusconi,G. Valpiani,C. Morotti,A. Borghi,
doi : 10.1111/jdv.17284
Volume 35, Issue 9 p. e578-e582
Sclerotherapy in a rare case of glomuvenous malformation (GVM) with severe skin manifestation
M.-L. Schiffmann,S.A. Braun,S. Jaegle,J. Fischer,T. Goerge,
doi : 10.1111/jdv.17295
Volume 35, Issue 9 p. e582-e583
Which patients present to dermatologic emergencies? A survey on 1561 patients
C. Skayem,A. Labonnelie,L. Fardet,K. Ezzedine,G. Hirsch,S. Ingen-Housz-Oro,P. Wolkenstein,O. Chosidow,T.A. Duong,
doi : 10.1111/jdv.17298
Volume 35, Issue 9 p. e583-e585
Toxic epidermal necrolysis-like acute cutaneous graft-versus-host disease in a stem cell recipient – a diagnostic dilemma
B. Klein,I. Kolm,G. Nair,M.C. Nägeli,
doi : 10.1111/jdv.17310
Volume 35, Issue 9 p. e585-e587
Male frontal fibrosing alopecia: study of 35 cases and association with sunscreens, facial skin and hair care products
D.C. Westphal,N. Caballero-Uribe,A. Regnier,P. Taguti,H. Dutra Rezende,R.M. Trüeb,
doi : 10.1111/jdv.17317
Volume 35, Issue 9 p. e587-e589
Prevalence of psoriasis in a cohort of children and adolescents with type 1 diabetes
F. Caroppo,A. Galderisi,C. Moretti,L. Ventura,A. Belloni Fortina,
doi : 10.1111/jdv.17318
Volume 35, Issue 9 p. e589-e591
Treatment-resistant bullous pemphigoid developing during therapy with immune checkpoint inhibitors
E. Povilaityte,F.F. Gellrich,S. Beissert,S. Abraham,F. Meier,C. Günther,
doi : 10.1111/jdv.17321
Volume 35, Issue 9 p. e591-e593
A nationwide multicentre cross-sectional questionnaire study on the use of non-dermatologic facilities among patients with hair loss
Jee Woong Choi,Dong Chan Kim,Bark Lynn Lew,Sang-Seok Kim,Chang Hun Huh,Moon-Bum Kim,Gwang Seong Choi,Hoon Kang,the Korean Society of Hair Research,
doi : 10.1111/jdv.17323
Volume 35, Issue 9 p. e594-e597
Single glycine deletion in COL7A1 acting as glycine substitution in dystrophic epidermolysis bullosa
R. Baardman,J. Bremer,G.F.H. Diercks,S.Z. Jan,H.H. Lemmink,M.C. Bolling,P.C. Van den Akker,
doi : 10.1111/jdv.17328
Volume 35, Issue 9 p. e597-e600
Calibre persistent artery of the nape
F. Allegue,C. Fachal,D. González-Vilas,J. González-Carreró Fojón,F.J. Hernández-Morales,A. Zulaica,
doi : 10.1111/jdv.17329
Volume 35, Issue 9 p. e600-e602
Prevalence and management of chronic nodular prurigo (CNPG) in Brittany (France): estimation by matching two databases
L. Misery,E. Brenaut,E. Torreton,J. Bonte,S. Bouée,
doi : 10.1111/jdv.17333
Volume 35, Issue 9 p. e602-e604
Harlequin syndrome
Z.-Q. Zhang,J. Zhang,Y.-F. Chen,
doi : 10.1111/jdv.17337
Volume 35, Issue 9 p. e604-e605
Harlequin syndrome with petechiae caused by a pituitary adenoma
H.O. Kim,J.C. Kim,B.Y. Chung,S.Y. Kang,C.W. Park,J.H. Han,
doi : 10.1111/jdv.17338
Volume 35, Issue 9 p. e605-e607
Is Scabies becoming less sensitive to permethrin therapy?
C. Mazzatenta,V. Piccolo,G. Argenziano,A. Bassi,
doi : 10.1111/jdv.17339
Volume 35, Issue 9 p. e607-e609
Smartphone data offer insights into disease activity and triggers in atopic dermatitis: a fully decentralized remote longitudinal pilot study
A. Eiken,C.P. Laugesen,A. Isberg,S.F. Thomsen,Z. Ali,A Chiriac,A.M. Dutei,I. Deaconescu,I. Manole,T.J. Valk,A.D. Andersen,J.R. Zibert,
doi : 10.1111/jdv.17205
Volume 35, Issue 9 p. e609-e612
Dupilumab and conjunctivitis: a case series of twenty patients
G. Calabrese,A. Gambardella,G. Licata,E.V. Di Brizzi,R. Alfano,G. Argenziano,
doi : 10.1111/jdv.17210
Volume 35, Issue 9 p. e612-e614
A phase I clinical trial to evaluate the safety of HU-045 for treating moderate-to-severe glabellar lines: a pilot study
H.S. Han,J.W. Park,K.H. Yoo,B.J. Kim,
doi : 10.1111/jdv.17369
Volume 35, Issue 9 p. e614-e617
Reply to ‘A case of anaphylactic shock induced by mealworm antigen in the bite of a Japanese flying squirrel’ by Seshimo et al.
C. Guillet,P. Schmid-Grendelmeier,
doi : 10.1111/jdv.17411
Volume 35, Issue 9 p. e617-e618
Response to ‘Reply to “A case of anaphylactic shock induced by mealworm antigen in the bite of a Japanese flying squirrel” by Seshimo et al.’ by Schmid-Grendelmeier and Guillet
H. Seshimo,T. Ito,C. Egusa,T. Numata,T. Kobayashi,N. Abe,T. Niitsuma,Y. Okubo,K. Harada,
doi : 10.1111/jdv.17415
Volume 35, Issue 9 p. e618-e618
